Results 1 to 10 of about 7,154 (184)

Efficacy of Nirmatrelvir-Ritonavir versus Azvudine for COVID-19 Treatment in Tibet: A Retrospective Study

Infection and Drug Resistance, 2023
Xiang Zhao,1 Yuan Cheng,1 Meng Zhang,1 Bianba Qianda,2 Baima Zhouma,3 Bianba Yangzhen,3 Yao Zheng,4 Shuo Zhang,5 Huiying Zhao6 1Department of Respiratory and Critical Care Medicine, Peking University First Hospital, Beijing, People’s Republic of China ...
Zhao X, Cheng Y, Zhang M, Qianda B, Zhouma B, Yangzhen B, Zheng Y, Zhang S, Zhao H   +8 more
doaj   +1 more source

Proportion of Patients in the United States Who Fill Their Nirmatrelvir/Ritonavir Prescriptions

Infectious Diseases and Therapy
Introduction Although real-world studies demonstrate that those prescribed nirmatrelvir/ritonavir (and particularly within 5 days of symptom onset) are less likely to experience severe COVID-19 outcomes, prior studies show that only a small fraction of ...
Abby E. Rudolph, Farid L. Khan, Tanya G. Singh, Srinivas Rao Valluri, Laura A. Puzniak, John M. McLaughlin   +5 more
doaj   +2 more sources

Early combination of sotrovimab with nirmatrelvir/ritonavir or remdesivir is associated with low rate of persisting SARS CoV-2 infection in immunocompromised outpatients with mild-to-moderate COVID-19: a prospective single-centre study

Annals of Medicine
Background Immunocompromised patients are at high risk of developing persisting/prolonged COVID-19. Data on the early combined use of antivirals and monoclonal antibodies in this population are scarce.Research design and methods We performed an ...
I. Gentile, G. Viceconte, F. Cuccurullo, D. Pietroluongo, A. D’Agostino, M. Silvitelli, S. Mercinelli, R. Scotto, F. Grimaldi, S. Palmieri, A. Gravetti, F. Trastulli, M. Moccia, A. R. Buonomo   +13 more
doaj   +1 more source

Nirmatrelvir-ritonavir for COVID-19 [PDF]

Canadian Medical Association Journal, 2022
McDonald, Emily G, Lee, Todd C
openaire   +2 more sources

Mitigating Paxlovid™-induced drug‒drug interaction toxicity: an in silico insight

Frontiers in Pharmacology
The clinical drug-drug interaction side-effects of Ritonavir, an ingredient in Paxlovid™, have been documented, highlighting the need to explore alternative administration methods for Nirmatrelvir, another drug in the Paxlovid™ combination. In this study,
Giang H. Ta, Max K. Leong
doaj   +1 more source

Effectiveness of Vaccines and Antiviral Drugs in Preventing Severe and Fatal COVID-19, Hong Kong

Emerging Infectious Diseases
We compared the effectiveness and interactions of molnupiravir and nirmatrelvir/ritonavir and 2 vaccines, CoronaVac and Comirnaty, in a large population of inpatients with COVID-19 in Hong Kong. Both the oral antiviral drugs and vaccines were associated
Yue Yat Harrison Cheung, Eric Ho Yin Lau, Guosheng Yin, Yun Lin, Benjamin J. Cowling, Kwok Fai Lam   +5 more
doaj   +1 more source

Exploring Paxlovid Efficacy in COVID-19 Patients with MAFLD: Insights from a Single-Center Prospective Cohort Study

Viruses
This study investigates the intricate interplay between Metabolic-associated Fatty Liver Disease (MAFLD) and COVID-19, exploring the impact of MAFLD on disease severity, outcomes, and the efficacy of the antiviral agent Paxlovid (nirmatrelvir/ritonavir).
Mykhailo Buchynskyi, Valentyn Oksenych, Iryna Kamyshna, Oleksandr Kamyshnyi   +3 more
doaj   +1 more source

Effect of Paxlovid in COVID-19 treatment during the periods of SARS-CoV-2 Omicron BA.5 and BN.1 subvariant dominance in the Republic of Korea: a retrospective cohort study [PDF]

Osong Public Health and Research Perspectives
Objectives This study was conducted to assess the efficacy of nirmatrelvir/ritonavir treatment in patients with coronavirus disease 2019 (COVID-19), particularly those aged 60 years and older.
Dong-Hwi Kim, Min-Gyu Yoo, Na-Young Kim, So Young Choi, Minjeong Jang, Misuk An, Se-Jin Jeong, Jungyeon Kim   +7 more
doaj   +1 more source

Drug-related problems and challenges encountered by pharmacists in nirmatrelvir/ritonavir counselling during the covid-19 pandemic: a multi-center study

Scientific Reports
Pharmacists’ counselling roles expanded significantly during the COVID-19 pandemic, yet drug-related problems (DRPs) and challenges during nirmatrelvir/ritonavir counselling remain underreported.
Shamala Balan, Kavidha Mohan, Vanitha Hong Wee Liang, Hanis Hazwanie Ghazali, Chew Li Suan, Chong Chia Chee, Kong Wei En, Leana Fatimah Makhdzir, Nurul Syafiqah Samsuri, Nor Mazni Mohamad Tamyes, Juliana Nazlim Lim, Nur Amirah Mohd Noor Azami, Suhaili Samad, Kiren Kaur Chut Singh, Nurfareeza Nazir Khan, Siti Hajar Chamati, Nurdiana Hassan, Kuay Hue Ping, Farraha Nordin, Lau Wai Hoong, Azlen Awatif Abu Bakar   +20 more
doaj   +1 more source

Nirmatrelvir plus ritonavir reduces COVID-19 hospitalization and prevents long COVID in adult outpatients

Scientific Reports
Nirmatrelvir plus ritonavir received Emergency Use Authorization for treating mild to moderate COVID-19 in high-risk patients. Its efficacy against the Omicron variant of SARS-CoV-2 remains uncertain.
Fatemeh Saheb Sharif-Askari, Hawra Ali Hussain Alsayed, Narjes Saheb Sharif-Askari, Ali Al Sayed Hussain, Saleh Al-Muhsen, Rabih Halwani   +5 more
doaj   +1 more source